• NanoViricides moved toward a Phase II trial of NV-387 to treat measles, with a draft protocol now in circulation.
• Clinical results have not been presented; the program is still being prepared for an FDA IND process.
• NV-387 is positioned as a potential measles treatment in a market with no approved drug option for infected patients.
• Strategic upside includes FDA Rare Pediatric Disease Drug status, which could support a Priority Review Voucher upon a successful marketing application.
• A recent Priority Review Voucher sale cited in the announcement was valued at USD 195 million, highlighting potential non-commercialization cash value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608310830ACCESSWRNAPR_____1214616) on August 31, 2026, and is solely responsible for the information contained therein.